EP0664127A2 - Pharmaceutical compositions containing isoquinoline derivatives - Google Patents
Pharmaceutical compositions containing isoquinoline derivatives Download PDFInfo
- Publication number
- EP0664127A2 EP0664127A2 EP94120240A EP94120240A EP0664127A2 EP 0664127 A2 EP0664127 A2 EP 0664127A2 EP 94120240 A EP94120240 A EP 94120240A EP 94120240 A EP94120240 A EP 94120240A EP 0664127 A2 EP0664127 A2 EP 0664127A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- agents
- isoquinoline derivatives
- acid
- present
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, ***e
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Definitions
- the present invention relates to a pharmaceutical composition which contains at least one isoquinoline derivative and/or a pharmaceutically-acceptable salt thereof as an active component.
- cyclic nucleotide phosphodiesterases which are enzymes that decompose the above substances.
- the cyclic nucleotide phosphodiesterases are often abbreviated as phosphodiesterases. They are classified into several isozymes and the molecular structure, the regulating functions, the distributions in tissues and in cells and the specificity of each of these isozymes have been clarified. At the same time, there have been brief investigations into inhibitors which are specific to the isozymes of the phosphodiesterases and some inhibitors which are useful as pharmaceuticals have been found.
- Phosphodiesterase type IV isozyme (hereinafter, referred to as PDEIV) which is one of the isozymes of the phosphodiesterases is distributed in tissues and cells such as brain, kidney, spermary, inflammatory cells, etc. It has a low Km value to CAMP and is an enzyme which specifically decomposes cAMP.
- the inhibitors for PDEIV exhibit various pharmacological actions such as an action to central nerves such as antidepressant, tranquillizing and antidemential actions, an antiiflammatory action due to inhibition of isolation of chemical mediators and also to inhibition of perfusion of neutrophils, a bronchodilating action, a relaxing action to smooth muscles, a protective action to livers, a diuretic action, etc.
- isoquinoline derivatives some of them have been known to exhibit pharmacological actions such as a pheripheral dilating action and an antispasmodic action. In fact, drotaverine and the like have already been used as pharmaceuticals.
- the present inventors carried out an extensive study on the new pharmacological actions of isoquinoline derivatives and found that the isoquinoline derivatives of the present invention have an excellent inhibiting activity with a high specificity to PDEIV.
- An object of the present invention is to offer novel pharmaceutical compositions containing isoquinoline derivatives having an excellent PDEIV-inhibiting action as an active component.
- the active component of the pharmaceutical composition according to the present invention is an isoquinoline derivative represented by the following general formula: [in which R is hydrogen or an alkoxy group]
- R is hydrogen or a linear or branched alkoxy group having one to ten carbon atoms such as methoxy, ethoxy, propoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tertbutoxy, pentoxy, isopentoxy, neopentoxy, tert-pentoxy, hexoxy, dimethylbutoxy, peptoxy, octoxy, de- soxy, etc.
- the isoquinoline derivatives according to the present invention also include pharmaceutically acceptable salts of the compounds repesented by the above general formula such as addition salts with hydrochloric acid, sulfuric acid, nitric acid, hydrobromic acid, phosphoric acid, perchloric acid, thiocyanic acid, boric acid, formic acid, acetic acid, haloacetic acid, propionic acid, glycolic acid, citric acid, tartaric acid, succinic acid, gluconic acid, lactic acid, malonic acid, fumaric acid, anthranilic acid, benzoic acid, cinnamic acid, p-toluenesulfonic acid, naphthalenesulfonic acid, sulfanilic acid, theophylline-acetic acid, etc.
- these salts with hydrochloric acid and theophylline-acetic acid are preferred.
- salts may be manufactured from the isoquinoline derivatives according to the present invention in a free state or mutually converted from one to another by conventional means.
- Stereoisomers such as cis-trans isomers, optical isomers, conformational isomers, etc. or hydrates of these compounds are also included in the present invention.
- Each of the isozymes of the phosphodiesterases was prepared by conventional means.
- 10 g of freeze-dried powder of porcine artery was homogenized by adding 5 times as much (v/w) of a buffer (comprising 0.25 M of sucrose, 10 mM of Tris hydrochloride (pH 7.8), 5 mM magnesium chloride, 0.2 mM ethylenebis(hydroxyethylenenitrilo)tetraacetic acid, 100 nM p-toluenesulfonyl fluoride, 100 nM leupeptine and 100 nM pepstatin) thereto.
- a buffer comprising 0.25 M of sucrose, 10 mM of Tris hydrochloride (pH 7.8), 5 mM magnesium chloride, 0.2 mM ethylenebis(hydroxyethylenenitrilo)tetraacetic acid, 100 nM p-toluenesulfonyl fluoride, 100 nM leupeptine and
- the mixture was centrifuged at 2,500 rpm for 20 minutes and the supernatant liquid was further centrifuged at 40,000 rpm for one hour.
- the resulting supernatant liquid was filtered and dialyzed to a solution (70 mM sodium acetate of pH 6.8 and 5mM of 2-mercaptoethanol) containing the same protease inhibitor as in the above buffer.
- the sample obtained by the dialysis was added to a DEAE-sepharose-FF column (Pharmacia) which was filled in a column equilibrated with the above-mentioned buffer and then eluted with a solution of sodium acetate having a linear graded concentration gradient of 0.07-1.0 M.
- the activity of the phosphodiesterase on the isozyme in the eluted fractions was measured. Fractions in which the activity was concentrated were collected for use as an enzyme source.
- isozymes of the types I, II, III, IV and V were eluted/fractionated into the fractions of 20 and 21; 30 and 31; 29; 61; and 67, respectively.
- a reaction system was prepared containing 50 mM Tris HCI (pH: 7.5), 6 mM magnesium chloride, 1 mM of ethylenebis(hydroxyethylenenitrilo)tetraacetic acid, 2.5 mM dithiothreitol, 2.5% dimethyl sulfoxide, 0.025 mg/ml 5'-nucleotide, 0.23 mg/ml bovine serum albumin and 1-5 ⁇ g of each enzyme (the figures represent the final concentrations).
- the reaction mixture solution was pre-incubated at 30 ° C for 5-10 minutes, [ 3 H]cAMP or [ 3 H]cGMP was added thereto and the mixture was incubated at 30 °C for 10-15 minutes.
- a cationic exchange resin suspended in water was added to the reaction solution in order to absorb the unreacted CAMP or cGMP and thus stop the reaction.
- the mixture was then centrifuged at 2,000 g for five minutes, a part of the supernatant liquid was taken out and subjected to a measurement of its radioactivity by means of a liquid scintillation counter.
- the substance to be tested dissolved in dimethyl sulfoxide or in water was added to the above reaction system and the inhibitory activity of said substance to each isozyme of the phosphodiesterase was measured.
- [ 3 H]-CAMP When the inhibitory activity of the test substance against the isozyme of type I was measured, [ 3 H]-CAMP was used as a substrate and 5 ⁇ g/ml calmodulin was made coexistent. In the case of the inhibitory activity measurement to the type II, [ 3 H]cAMP was used as a substrate and 10 ⁇ M cGMP was made coexistent. In the case of the type III, [ 3 H]cAMP was used as a substrate and 100 ⁇ M Ro20-1724 (4-[(3-butoxy-4-methoxyphenyl)methyl]-2-imidazolidinone; an inhibitor which is specific to the type IV) was made coexistent.
- [ 3 H]cAMP was used as a substrate and 10 ⁇ M of cilostazol (an inhibitor which is specific to the type III) was made coexistent.
- [ 3 H]cGMP was used as a substrate.
- the inhibitory activity to phosphodiesterase isozymes was measured according to the above-mentioned test method and the results show that the compounds according to the present invention exhibited a strong inhibitory action especially to the isozyme of the type IV.
- An example of the results is given in Table 1.
- the concentration of CAMP in the tissue increases when the PDEIV is inhibited and therefore actions on central nerves such as antidepressive action, tranquilizing action, antidemential action, etc., antiinflammatory action due to inhibiting the isolation of chemical mediators and the perfusion of neutrophils, bronchodilating action, relaxing action for smooth muscles, liver-protecting action, diuretic action, etc. have been suggested as the pharmcological effect of the PDEIV inhibitors.
- the compounds according to the present invention are of great use in pharmaceuticals such as antidepressive agents, tranquilizing agents, antidemential agents, antiinflammatory agents, antiallergic agents, antiasthmatic agents, liver-protecting agents, diuretic agents, etc., and also in medicaments for the prevention and therapy of various diseases including distortions of the central nervous system such as depression and dementia as well as others such as inflammation, allergic diseases, asthma, liver diseases, kidney diseases, etc.
- the compounds according to the present invention can be used to formulate pharmaceutical preparations by combining them with suitable pharmaceutical carriers or diluents.
- the formulations include various types of preparations obtainable by common methods such as solids, semisolids, liquids or aerosol formulations for oral or parenteral administration.
- the compounds according to the present invention may be used either on their own or in combination with pharmaceutically-active components.
- the compounds according to the present invention may be used alone or together with commonly used excipients. They may for example be blended with suitable additives (e.g. lactose, sugar, glucose, mannitol, corn starch, potato starch, etc.), binders such as crystalline cellulose, cellulose derivatives, gum arabicum, tragacanth solution, sodium alginate solution, gelatin, etc., disintegrating agents such as corn starch, potato starch, potassium carboxymethylcellulose, etc., lubricating agents such as talc, magnesium stearate, etc. and others including bulking agents, moisturizing agents, buffers, preservatives, perfumes and the like to give tablets, diluted powders, granules or capsules.
- suitable additives e.g. lactose, sugar, glucose, mannitol, corn starch, potato starch, etc.
- binders such as crystalline cellulose, cellulose derivatives, gum arabicum, tragacanth solution, sodium alginate solution
- suppositories may be prepared by blending with fatty/oily bases (e.g. cacao butter), emulsified bases, watersoluble bases (e.g. Macrogol), hydrophilic bases, etc.
- fatty/oily bases e.g. cacao butter
- emulsified bases e.g. cacao butter
- watersoluble bases e.g. Macrogol
- hydrophilic bases etc.
- aqueous and nonaqueous solvents such as distilled water for injection, physiological saline solution, Ringer's solution, plant oil, synthetic fatty acid glycerides, higher fatty acid esters, propylene glycol, etc.
- compositions other than those mentioned above, which are suitable for therapeutic application as, for example, inhalating agents, aerosol agents, ointments, poultices, eye drops, etc.
- the preferred dose of the compounds according to the present invention may vary depending upon the patient's individiual requirements (i.e. age, body weight, symptoms, etc.), form of the preparation, method of administration, period of administration etc. In order to achieve the desired effect a 10-2,000 mg per day may normally be administered orally to the average adult either in a single dosage or in several smaller doses.
Abstract
Description
- The present invention relates to a pharmaceutical composition which contains at least one isoquinoline derivative and/or a pharmaceutically-acceptable salt thereof as an active component.
- An action of regulating the cell functions of CAMP and cGMP as intracellular information transmitters has been clarified and investigations have also been made into the cyclic nucleotide phosphodiesterases which are enzymes that decompose the above substances. The cyclic nucleotide phosphodiesterases are often abbreviated as phosphodiesterases. They are classified into several isozymes and the molecular structure, the regulating functions, the distributions in tissues and in cells and the specificity of each of these isozymes have been clarified. At the same time, there have been brief investigations into inhibitors which are specific to the isozymes of the phosphodiesterases and some inhibitors which are useful as pharmaceuticals have been found.
- Phosphodiesterase type IV isozyme (hereinafter, referred to as PDEIV) which is one of the isozymes of the phosphodiesterases is distributed in tissues and cells such as brain, kidney, spermary, inflammatory cells, etc. It has a low Km value to CAMP and is an enzyme which specifically decomposes cAMP. When the PDEIV is inhibited, the concentration of CAMP in the tissues increases and, therefore, it has been known that the inhibitors for PDEIV exhibit various pharmacological actions such as an action to central nerves such as antidepressant, tranquillizing and antidemential actions, an antiiflammatory action due to inhibition of isolation of chemical mediators and also to inhibition of perfusion of neutrophils, a bronchodilating action, a relaxing action to smooth muscles, a protective action to livers, a diuretic action, etc.
- With respect to isoquinoline derivatives, some of them have been known to exhibit pharmacological actions such as a pheripheral dilating action and an antispasmodic action. In fact, drotaverine and the like have already been used as pharmaceuticals. The present inventors carried out an extensive study on the new pharmacological actions of isoquinoline derivatives and found that the isoquinoline derivatives of the present invention have an excellent inhibiting activity with a high specificity to PDEIV.
- An object of the present invention is to offer novel pharmaceutical compositions containing isoquinoline derivatives having an excellent PDEIV-inhibiting action as an active component.
-
- In the above formula, R is hydrogen or a linear or branched alkoxy group having one to ten carbon atoms such as methoxy, ethoxy, propoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tertbutoxy, pentoxy, isopentoxy, neopentoxy, tert-pentoxy, hexoxy, dimethylbutoxy, peptoxy, octoxy, de- soxy, etc. The isoquinoline derivatives according to the present invention also include pharmaceutically acceptable salts of the compounds repesented by the above general formula such as addition salts with hydrochloric acid, sulfuric acid, nitric acid, hydrobromic acid, phosphoric acid, perchloric acid, thiocyanic acid, boric acid, formic acid, acetic acid, haloacetic acid, propionic acid, glycolic acid, citric acid, tartaric acid, succinic acid, gluconic acid, lactic acid, malonic acid, fumaric acid, anthranilic acid, benzoic acid, cinnamic acid, p-toluenesulfonic acid, naphthalenesulfonic acid, sulfanilic acid, theophylline-acetic acid, etc. Amongst these salts with hydrochloric acid and theophylline-acetic acid are preferred.
- These salts may be manufactured from the isoquinoline derivatives according to the present invention in a free state or mutually converted from one to another by conventional means. Stereoisomers such as cis-trans isomers, optical isomers, conformational isomers, etc. or hydrates of these compounds are also included in the present invention.
- Examples of compounds according to the present invention which are particularly preferred are as follows:
- 1-Benzyl-3,4-dihydroisoquinoline [Compound 1] 1-(3',4'-Dimethoxybenzyl)-6,7-dimethoxy-3,4-dihydroisoquinoline [Compound 2] 1-(3',4'-Diethoxybenzyl)-6,7-diethoxy-3,4-dihydroisoquinoline [Compound 3] 1-(3',4'-Diethoxybenzyl)-6,7-diethoxy-3,4-dihydroisoquinoline hydrochloride [Compound 4] 1-(3',4'-Diethoxybenzyl)-6,7-diethoxy-3,4-dihydroisoquinoline-theophylline-7-acetate [Compound 5] 1-(3',4'-Diethoxybenzyl)-6,7-diethoxy-3,4-dihydroisoquinoline-theophylline-7-acetate monohydrate [Compound 6]
- The above compounds have been disclosed, for example, in the Japanese Laid-Open Patent Publications 50/046818, 62/167781 and 62/187411. They can be prepared by known methods.
- In the following pharmacological actions of the isoquinoline derivatives of the present invention will be shown.
- Each of the isozymes of the phosphodiesterases was prepared by conventional means. Thus, 10 g of freeze-dried powder of porcine artery was homogenized by adding 5 times as much (v/w) of a buffer (comprising 0.25 M of sucrose, 10 mM of Tris hydrochloride (pH 7.8), 5 mM magnesium chloride, 0.2 mM ethylenebis(hydroxyethylenenitrilo)tetraacetic acid, 100 nM p-toluenesulfonyl fluoride, 100 nM leupeptine and 100 nM pepstatin) thereto. The mixture was centrifuged at 2,500 rpm for 20 minutes and the supernatant liquid was further centrifuged at 40,000 rpm for one hour. The resulting supernatant liquid was filtered and dialyzed to a solution (70 mM sodium acetate of pH 6.8 and 5mM of 2-mercaptoethanol) containing the same protease inhibitor as in the above buffer.
- The sample obtained by the dialysis was added to a DEAE-sepharose-FF column (Pharmacia) which was filled in a column equilibrated with the above-mentioned buffer and then eluted with a solution of sodium acetate having a linear graded concentration gradient of 0.07-1.0 M. The activity of the phosphodiesterase on the isozyme in the eluted fractions was measured. Fractions in which the activity was concentrated were collected for use as an enzyme source. In the present test system, isozymes of the types I, II, III, IV and V were eluted/fractionated into the fractions of 20 and 21; 30 and 31; 29; 61; and 67, respectively.
- A reaction system was prepared containing 50 mM Tris HCI (pH: 7.5), 6 mM magnesium chloride, 1 mM of ethylenebis(hydroxyethylenenitrilo)tetraacetic acid, 2.5 mM dithiothreitol, 2.5% dimethyl sulfoxide, 0.025 mg/ml 5'-nucleotide, 0.23 mg/ml bovine serum albumin and 1-5 µg of each enzyme (the figures represent the final concentrations). The reaction mixture solution was pre-incubated at 30 ° C for 5-10 minutes, [3H]cAMP or [3H]cGMP was added thereto and the mixture was incubated at 30 °C for 10-15 minutes. A cationic exchange resin suspended in water was added to the reaction solution in order to absorb the unreacted CAMP or cGMP and thus stop the reaction. The mixture was then centrifuged at 2,000 g for five minutes, a part of the supernatant liquid was taken out and subjected to a measurement of its radioactivity by means of a liquid scintillation counter. The substance to be tested dissolved in dimethyl sulfoxide or in water was added to the above reaction system and the inhibitory activity of said substance to each isozyme of the phosphodiesterase was measured.
- When the inhibitory activity of the test substance against the isozyme of type I was measured, [3H]-CAMP was used as a substrate and 5 µg/ml calmodulin was made coexistent. In the case of the inhibitory activity measurement to the type II, [3H]cAMP was used as a substrate and 10 µM cGMP was made coexistent. In the case of the type III, [3H]cAMP was used as a substrate and 100 µM Ro20-1724 (4-[(3-butoxy-4-methoxyphenyl)methyl]-2-imidazolidinone; an inhibitor which is specific to the type IV) was made coexistent. In the case of the type IV, [3H]cAMP was used as a substrate and 10 µM of cilostazol (an inhibitor which is specific to the type III) was made coexistent. In the case of the measurement of the type V, [3H]cGMP was used as a substrate.
- The inhibitory activity to phosphodiesterase isozymes was measured according to the above-mentioned test method and the results show that the compounds according to the present invention exhibited a strong inhibitory action especially to the isozyme of the type IV. An example of the results is given in Table 1.
- It is apparent from the result given in Table 1 that the compounds according to the present invention exhibited a PDEIV-inhibiting activity the same as or even higher than that of Ro20-1724 which was known as a very specific RDEIV inhibitor. Furthermore, it can be understood that the resulting PDEIV-inhibiting activity was very specific. In fact, it was at least 10 times stronger than that of of other types of PDE isozymes.
- As mentioned already, the concentration of CAMP in the tissue increases when the PDEIV is inhibited and therefore actions on central nerves such as antidepressive action, tranquilizing action, antidemential action, etc., antiinflammatory action due to inhibiting the isolation of chemical mediators and the perfusion of neutrophils, bronchodilating action, relaxing action for smooth muscles, liver-protecting action, diuretic action, etc. have been suggested as the pharmcological effect of the PDEIV inhibitors.
- Consequently, the compounds according to the present invention are of great use in pharmaceuticals such as antidepressive agents, tranquilizing agents, antidemential agents, antiinflammatory agents, antiallergic agents, antiasthmatic agents, liver-protecting agents, diuretic agents, etc., and also in medicaments for the prevention and therapy of various diseases including distortions of the central nervous system such as depression and dementia as well as others such as inflammation, allergic diseases, asthma, liver diseases, kidney diseases, etc.
- The compounds according to the present invention can be used to formulate pharmaceutical preparations by combining them with suitable pharmaceutical carriers or diluents. The formulations include various types of preparations obtainable by common methods such as solids, semisolids, liquids or aerosol formulations for oral or parenteral administration.
- For these preparations, the compounds according to the present invention may be used either on their own or in combination with pharmaceutically-active components.
- In the case of preparations for oral administration, the compounds according to the present invention may be used alone or together with commonly used excipients. They may for example be blended with suitable additives (e.g. lactose, sugar, glucose, mannitol, corn starch, potato starch, etc.), binders such as crystalline cellulose, cellulose derivatives, gum arabicum, tragacanth solution, sodium alginate solution, gelatin, etc., disintegrating agents such as corn starch, potato starch, potassium carboxymethylcellulose, etc., lubricating agents such as talc, magnesium stearate, etc. and others including bulking agents, moisturizing agents, buffers, preservatives, perfumes and the like to give tablets, diluted powders, granules or capsules.
- Alternatively, suppositories may be prepared by blending with fatty/oily bases (e.g. cacao butter), emulsified bases, watersoluble bases (e.g. Macrogol), hydrophilic bases, etc.
- In the case of injections, it is possible to prepare solutions or the suspensions in an aqueous and nonaqueous solvents such as distilled water for injection, physiological saline solution, Ringer's solution, plant oil, synthetic fatty acid glycerides, higher fatty acid esters, propylene glycol, etc.
- It is also possible, depending upon the state of the patient and the type of the disease, to prepare pharmaceutical compositions, other than those mentioned above, which are suitable for therapeutic application as, for example, inhalating agents, aerosol agents, ointments, poultices, eye drops, etc.
- The preferred dose of the compounds according to the present invention may vary depending upon the patient's individiual requirements (i.e. age, body weight, symptoms, etc.), form of the preparation, method of administration, period of administration etc. In order to achieve the desired effect a 10-2,000 mg per day may normally be administered orally to the average adult either in a single dosage or in several smaller doses.
- In the case of a parenteral administration e.g. by injection it is preferable, due to the influence of the absorption, etc., for a quantity of 1/3 to 1/10 of the above oral dose to be administered.
-
Claims (6)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP35148193A JP3276762B2 (en) | 1993-12-28 | 1993-12-28 | Pharmaceutical composition containing isoquinoline derivative |
JP351481/93 | 1993-12-28 | ||
JP35148193 | 1993-12-28 |
Publications (3)
Publication Number | Publication Date |
---|---|
EP0664127A2 true EP0664127A2 (en) | 1995-07-26 |
EP0664127A3 EP0664127A3 (en) | 1999-12-29 |
EP0664127B1 EP0664127B1 (en) | 2002-03-06 |
Family
ID=18417586
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP94120240A Expired - Lifetime EP0664127B1 (en) | 1993-12-28 | 1994-12-20 | Pharmaceutical compositions containing isoquinoline derivatives |
Country Status (6)
Country | Link |
---|---|
US (1) | US5556862A (en) |
EP (1) | EP0664127B1 (en) |
JP (1) | JP3276762B2 (en) |
AT (1) | ATE213942T1 (en) |
DE (1) | DE69430047T2 (en) |
ES (1) | ES2173901T3 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001049275A2 (en) * | 1999-12-29 | 2001-07-12 | Queen's University At Kingston | Methods and compositions for mitigating pain using nitrate esters |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1296985B1 (en) * | 1997-12-19 | 1999-08-03 | Zambon Spa | BENZAZINIC DERIVATIVES INHIBITORS OF PHOSPHODIESTERASE 4 |
IT1302677B1 (en) | 1998-10-15 | 2000-09-29 | Zambon Spa | BENZAZINIC DERIVATIVES INHIBITORS OF PHOSPHODIESTERASE 4 |
US6562837B1 (en) * | 1998-10-21 | 2003-05-13 | Korea Institute Of Science & Technology | Use of tetrahydroisoquinoline compounds for the treatment of septicemia |
IL149106A0 (en) * | 2001-04-20 | 2002-11-10 | Pfizer Prod Inc | Therapeutic use of selective pde10 inhibitors |
EP2156847A1 (en) * | 2008-08-19 | 2010-02-24 | Sanofi-Aventis | New combination of active ingredients containing an alpha1-antagonist and a PDE 4 inhibitor. |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2181432A (en) * | 1985-10-03 | 1987-04-23 | Chinoin Gyogyszer Es Vegyeszet | Chemical process |
EP0227356A2 (en) * | 1985-12-04 | 1987-07-01 | CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. | The use of depogen in the treatment of restricted blood circulation |
US4956371A (en) * | 1989-09-19 | 1990-09-11 | Euroceltique, S.A. | Substituted isoquinolines and methods of using same |
WO1992003137A1 (en) * | 1990-08-23 | 1992-03-05 | The Children's Medical Center Corporation | Treatment of aids dementia, myelopathy, peripheral neuropathy, and vision loss |
EP0513997A1 (en) * | 1991-04-12 | 1992-11-19 | CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. | Antithrombotic compositions |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU167246B (en) * | 1973-01-25 | 1975-09-27 |
-
1993
- 1993-12-28 JP JP35148193A patent/JP3276762B2/en not_active Expired - Fee Related
-
1994
- 1994-12-20 EP EP94120240A patent/EP0664127B1/en not_active Expired - Lifetime
- 1994-12-20 AT AT94120240T patent/ATE213942T1/en active
- 1994-12-20 ES ES94120240T patent/ES2173901T3/en not_active Expired - Lifetime
- 1994-12-20 DE DE69430047T patent/DE69430047T2/en not_active Expired - Lifetime
- 1994-12-21 US US08/360,630 patent/US5556862A/en not_active Expired - Lifetime
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2181432A (en) * | 1985-10-03 | 1987-04-23 | Chinoin Gyogyszer Es Vegyeszet | Chemical process |
EP0227356A2 (en) * | 1985-12-04 | 1987-07-01 | CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. | The use of depogen in the treatment of restricted blood circulation |
US4956371A (en) * | 1989-09-19 | 1990-09-11 | Euroceltique, S.A. | Substituted isoquinolines and methods of using same |
WO1992003137A1 (en) * | 1990-08-23 | 1992-03-05 | The Children's Medical Center Corporation | Treatment of aids dementia, myelopathy, peripheral neuropathy, and vision loss |
EP0513997A1 (en) * | 1991-04-12 | 1992-11-19 | CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. | Antithrombotic compositions |
Non-Patent Citations (6)
Title |
---|
DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US KAPUI, ZOLTAN ET AL: "Indomethacin salts." retrieved from STN Database accession no. 120:62267 XP002117610 & HU 63 387 A (CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT., HUNG.) 1991 * |
KUKOVETZ, WALTHER R. ET AL: "Inhibition of cyclic-3',5'-nucleotide- phosphodiesterase as a possible mode of action of papaverine and similarly acting drugs" NAUNYN-SCHMIEDEBERGS ARCH. PHARMAKOL. ( 1970 ), 267(2), 189-94 , XP002117608 * |
LUGNIER, C. ET AL: "Analysis of the specificity of inhibitors against some cyclic phosphodiesterases by multiparametric techniques" PHARMAZIE ( 1992 ), 47(1), 46-9 , XP002050965 * |
MATTYUS, A.: "Comparison of No-Spa and Vasalgin for the treatment of headaches associated with vasomotor and cerebral disorders" THER. HUNG. (1968), 16(2), 71-4 , XP002117606 * |
POECH, GERALD ET AL: "Differentiation of intestinal smooth muscle relaxation caused by drugs that inhibit phosphodiesterase" NAUNYN-SCHMIEDEBERG'S ARCH. PHARMACOL. ( 1976 ), 293(3), 257-68 , XP002117609 * |
STOICHEV, TS. ET AL: "Screening pharmacological studies of four dihydroisoquinoline derivatives" ACTA PHYSIOL. PHARMACOL. BULG. ( 1979 ), 5(3), 82-90 , XP002117607 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001049275A2 (en) * | 1999-12-29 | 2001-07-12 | Queen's University At Kingston | Methods and compositions for mitigating pain using nitrate esters |
WO2001049275A3 (en) * | 1999-12-29 | 2001-12-13 | Univ Kingston | Methods and compositions for mitigating pain using nitrate esters |
US7115661B1 (en) | 1999-12-29 | 2006-10-03 | Queen's University At Kingston | Methods and compositions for mitigating pain |
Also Published As
Publication number | Publication date |
---|---|
EP0664127B1 (en) | 2002-03-06 |
JPH07196509A (en) | 1995-08-01 |
DE69430047D1 (en) | 2002-04-11 |
ATE213942T1 (en) | 2002-03-15 |
DE69430047T2 (en) | 2002-10-17 |
JP3276762B2 (en) | 2002-04-22 |
ES2173901T3 (en) | 2002-11-01 |
EP0664127A3 (en) | 1999-12-29 |
US5556862A (en) | 1996-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1278522B1 (en) | Pde-v inhibitors for treatment of parkinson's disease | |
Chen et al. | Effect of the plant-extract osthole on the relaxation of rabbit corpus cavernosum tissue in vitro | |
CZ212394A3 (en) | Enantiomeric hydroxy-xanthine derivatives | |
IE80710B1 (en) | Ranolazine and related piperazines used in the treatment of tissues experiencing a physical or chemical insult | |
BRPI0017067B1 (en) | cell division inhibitor, dehydrogenase, method for producing a cell division inhibitor and compound | |
US20050209243A1 (en) | Theophylline-based soluble guanylyl cyclase activators KMUP-1 analogues enhanced cyclic GMP and K+ channel activities on rabbit corpus cavernosum smooth muscle and intercavernous pressure activities | |
EP0771563B1 (en) | Use of 5-HT1A receptor ligands for the treatment of glaucoma | |
KR0148645B1 (en) | Cardiac protective | |
EP0779074B1 (en) | Protective agent for organ or tissue | |
EP0610519B1 (en) | Anti-hiv drug | |
US5292765A (en) | Neuroprotection by indolactam V and derivatives thereof | |
EP0664127B1 (en) | Pharmaceutical compositions containing isoquinoline derivatives | |
US6979687B1 (en) | Theophylline-based soluble guanylyl cyclase activators KMUP-1 analogues enhanced cyclic GMP and K+ channel activities on rabbit corpus cavernosum smooth muscle and intercavernous pressure activities | |
CA2149691A1 (en) | Medicament for therapeutic and prophylactic treatment of diseases caused by smooth muscle cell hyperplasia | |
JP3251673B2 (en) | How to control nitric oxide production | |
AU2017204652B2 (en) | Treatment of Type I and Type II diabetes | |
US20030171379A1 (en) | Methods of treating, preventing, or inhibiting inflammation with Mactanamide compounds | |
EP0081581B1 (en) | Compositions for treating glaucoma | |
EP0448029A2 (en) | Novel pharmaceutical uses of forskolin derivatives | |
JP3782001B2 (en) | Antidepressant and anxiolytic agents containing isoquinoline derivatives | |
CN105535951A (en) | Ulinastatin injection and preparation method for same | |
ES2378374T3 (en) | PDE 4 inhibitors for the treatment of interstitial cystitis | |
PT98785A (en) | PROCESS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS WITH REGULATORY ACID OF LIPIDS CONTAINING DECAGONAL NUCLEAR LACTONES | |
US4469707A (en) | Method for treatment of senile dementia | |
US7026344B2 (en) | Treating sickle cell disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH DE ES FR GB IT LI |
|
17P | Request for examination filed |
Effective date: 19981103 |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE CH DE ES FR GB IT LI |
|
17Q | First examination report despatched |
Effective date: 20001024 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7A 61K 31/472 A |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE ES FR GB IT LI |
|
REF | Corresponds to: |
Ref document number: 213942 Country of ref document: AT Date of ref document: 20020315 Kind code of ref document: T |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: E. BLUM & CO. PATENTANWAELTE Ref country code: CH Ref legal event code: EP |
|
REF | Corresponds to: |
Ref document number: 69430047 Country of ref document: DE Date of ref document: 20020411 |
|
ET | Fr: translation filed | ||
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2173901 Country of ref document: ES Kind code of ref document: T3 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20021209 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PFA Owner name: NIPPON ZOKI PHARMACEUTICAL CO., LTD. Free format text: NIPPON ZOKI PHARMACEUTICAL CO., LTD.#1-2, HIRANOMACHI NICHOME#CHUO-KU, OSAKA (JP) -TRANSFER TO- NIPPON ZOKI PHARMACEUTICAL CO., LTD.#1-2, HIRANOMACHI NICHOME#CHUO-KU, OSAKA (JP) |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20131224 Year of fee payment: 20 Ref country code: GB Payment date: 20131216 Year of fee payment: 20 Ref country code: CH Payment date: 20131213 Year of fee payment: 20 Ref country code: DE Payment date: 20131219 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20131216 Year of fee payment: 20 Ref country code: IT Payment date: 20131216 Year of fee payment: 20 Ref country code: ES Payment date: 20131209 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20131216 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 69430047 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 69430047 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Expiry date: 20141219 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20141219 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK07 Ref document number: 213942 Country of ref document: AT Kind code of ref document: T Effective date: 20141220 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20150330 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20141221 |